Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
Zoltán Hujber(Semmelweis University), Anna Sebestyén(Semmelweis University)
Cited by 23
Related Papers
Hypoxia Signaling in Cancer: From Basics to Clinical Practice
|Pathology & Oncology Research|2021|109
Activity and complexes of mTOR in diffuse large B-cell lymphomas—a tissue microarray study
|Modern Pathology|2012|25
Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells
|Cancer Cell International|2018|19
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells
|Pathology & Oncology Research|2019|18
Characterisation of bioenergetic pathways and related regulators by multiple assays in human tumour cells
|Cancer Cell International|2016|5